Market Chameleon (Mon, 20-Apr 4:12 AM ET)
Globe Newswire (Mon, 20-Apr 7:50 AM ET)
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Globe Newswire (Tue, 7-Apr 7:50 AM ET)
Globe Newswire (Mon, 30-Mar 4:46 PM ET)
Artelo Biosciences Secures $11 Million in Private Placement—Key Takeaways for Investors
Market Chameleon (Fri, 27-Mar 7:07 AM ET)
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Globe Newswire (Fri, 27-Mar 10:40 AM ET)
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Globe Newswire (Wed, 25-Mar 4:05 PM ET)
Artelo Biosciences Broadens Therapeutic Reach with Fully Funded Entry into $16.3B Glaucoma Market
Market Chameleon (Wed, 25-Mar 3:53 AM ET)
Globe Newswire (Wed, 25-Mar 7:31 AM ET)
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
Globe Newswire (Wed, 18-Mar 10:41 AM ET)
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences trades on the NASDAQ stock market under the symbol ARTL.
As of April 24, 2026, ARTL stock price climbed to $4.03 with 209,813 million shares trading.
ARTL has a beta of -1.38, meaning it tends to be less sensitive to market movements. ARTL has a correlation of 0.01 to the broad based SPY ETF.
ARTL has a market cap of $3.79 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ARTL traded as high as $85.80 and as low as $2.96.
The top ETF exchange traded funds that ARTL belongs to (by Net Assets): VXF.
ARTL has underperformed the market in the last year with a price return of -78.2% while the SPY ETF gained +31.9%. ARTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.3% and -32.2%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
ARTL support price is $3.29 and resistance is $4.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTL shares will trade within this expected range on the day.
